Share this post on:

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 04/2022”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of April 2022, we identify the following current VC trends in the US-Biotech sector:

  • In 2022, overall Biotech funding in the USA has reached USD 12,289m so far
  • Top 5 deals exceed USD 190m each, largest transaction amounted to USD 3,000m in Altos Labs
  • Catalio Capital Management (USA) leads the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and OrbiMed (USA)
  • Central Nervous System dominates as the top indication

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link

Source link

Share this post on:

Leave a Comment

Your email address will not be published.